The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
Alkermes (NASDAQ:ALKS) has received mixed analyst ratings over the past three months, with an average 12-month price target of $32.5, reflecting a 12.07% increase from the previous target. Analysts from Baird, UBS, Piper Sandler, and B of A Securities have provided varying ratings and price targets, indicating diverse perspectives on the company's performance. Alkermes, a biotechnology firm, has shown significant revenue growth and profitability, with a notable net margin and ROE, despite a market capitalization below industry averages.
March 19, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alkermes has received mixed analyst ratings, with an updated average 12-month price target of $32.5, indicating a positive outlook from some analysts despite varied perspectives. The company's strong financial performance, including significant revenue growth and profitability, supports a potentially positive short-term impact on its stock price.
The mixed analyst ratings with an increased average price target suggest a cautiously optimistic outlook for Alkermes. The company's strong financial performance, particularly in revenue growth and profitability, is likely to positively influence investor sentiment and potentially lead to a short-term increase in stock price. However, the diversity in analyst opinions indicates that investors should closely monitor further analyst updates and company performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100